Calls for papers
-
Aptar Pharma has announced the addition of molding capabilities to its OINDP manufacturing facility in Mumbai, India, which was opened in 2023. Products produced at the plant include MDI valves, breath-actuated inhalers, and nasal delivery devices.… Read more . . .
-
CDMO Bespak, which recently said that it had partnered with Upperton to offer nasal drug/device development and manufacturing and launched a new soft mist intranasal delivery device, has announced that it will now offer access… Read more . . .
-
Lupin has announced the approval of its Formoflo-G glypocyrronium / formoterol / fluticasone propionate MDI for the treatment of COPD by the Drug Controller General of India (DCGI) and the subsequent launch of the inhaler… Read more . . .
-
A judge in the United States District Court for the District of Delaware has found infringement by Liquidia of two claims included in US Patent No. 11,826,327 (“Treatment for interstitial lung disease”), which was issued… Read more . . .
-
CDMO Bespak, which recently announced a collaboration with Upperton to offer complete nasal drug/device development and manufacturing services, has now announced the launch of a new soft mist nasal delivery device called NasaDose Ultra Soft Unit… Read more . . .
-
Nasus Pharma has announced the initiation of a Phase 1 PK study of its NS003 nasal powder ondansetron, which the company is developing for the treatment of nausea and vomiting following surgical procedures or chemotherapy.… Read more . . .
-
California-based startup Mosanna Therapeutics, which raised $80 million last year for clinical development of MOS118 nasal spray for the treatment of obstructive sleep apnea, said that results from a Phase 1 study support progression into… Read more . . .
-
Tiziana Life Sciences has announced the initiation of the Phase 2a Healey ALS MyMatch BANYAN trial of intranasal foralumab in people with amyotrophic lateral sclerosis. The company announced in November 2024 the ALS Association would… Read more . . .
-
Kither Biotech has announced the initiation of a Phase 1b /2a study of KIT2014 inhaled PDE3/4 inhibitor in patients with COPD. The company recently announced results from a Phase 1 trial of KIT2014 in healthy… Read more . . .
-
Harro Höfliger says that dry-filling technology for metered dose inhaler production, which has previously been available only at laboratory scale, is now available for commercial scale production lines. Dry filling, which Harro has developed in… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
December 9-December 11: DDL 2026, Edinburgh, Scotland
April 27-30: RDD Europe 2027, Antibes, France
May 12-13: USP Joint Workshop: Quality and Product Performance Testing of Orally Inhaled and Nasal Drug Products, Rockville, MD, USA
June 30: RespireX 2027, Boston, MA, USA